Pyxis Oncology, Inc.
PYXS
$2.62
$0.020.77%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 17.71% | -19.88% | 13.25% | 40.52% | -67.76% |
| Total Depreciation and Amortization | 449.72% | -1.50% | -3.08% | 0.36% | -24.76% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -29.99% | 18.53% | -12.97% | -88.09% | 1,384.75% |
| Change in Net Operating Assets | -47.58% | 408.67% | 61.60% | 30.98% | -254.90% |
| Cash from Operations | 21.47% | 23.09% | 23.39% | -16.82% | -31.54% |
| Capital Expenditure | 100.00% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 41.65% | -24.99% | -3.27% | -40.65% | 333,312.50% |
| Cash from Investing | 41.76% | -25.05% | -3.27% | -40.65% | 333,312.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -787.50% | 88.06% | -3,250.00% | 99.97% | -764,900.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 8,462.50% | 88.06% | -- | -100.00% | -96.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 458.49% | 10.46% | 69.82% | -190.52% | 156.97% |